Barinthus Biotherapeutics plc.

Listed Company

BRNSCIK 0001828185NasdaqEmerging GrowthPharmaceutical PreparationsX0GBFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-66.43M

Total Assets

$98.17M

Equity

$74.21M

Shares Out

40.85M

Op. Cash Flow

$-47.98M

Business

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases, as well as infectious diseases and oncology. It offers product candidates built on a SNAP-TI immune tolerance platform (lead candidate VTP-1000 for celiac disease) and viral vector platforms ChAdOx and MVA with programs such as VTP-300 (HBV), VTP-850 (prostate cancer), VTP-200 (HPV) and prophylactic vaccines. Its operations are organized around two core platforms—immune tolerance (SNAP-TI) and CD8+ T cell induction (viral vectors)—alongside licensing, partnerships and clinical development. Barinthus conducts global clinical trials and advances programs through collaborations and partner-mediated manufacturing and commercialization channels across the U.K., U.S., Europe, Australia and other international markets.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	0	15	802,000	45	268,000
Research and development	26	42	45	42	20
General and administrative	41	30	40	6	25
Impairment of intangible assets	5	0	—	—	—
Goodwill impairment	0	12	0	—	—
Total operating expenses	71	84	85	49	45
Other operating income	506,000	1	0	—	—
Loss from operations	−71	−68	−84	−4	−45
Interest income	2	3	3	3	2,000
Interest expense	−51,000	−53,000	−28,000	—	—
Research and development incentives	2	4	4	1	4
Other income	16,000	135,000	1	567,000	332,000
Total other income, net	4	7	7	5	−6
Loss before income tax	−67	−61	−77	850,000	−51
Tax benefit	175,000	44,000	3	4	28,000
Net loss	−66	−61	−73	5	−51
Net loss attributable to noncontrolling interest	30,000	109,000	100,000	21,000	247,000
Net loss attributable to Barinthus Biotherapeutics plc shareholders	−66	−61	−73	5	−51
Weighted-average ordinary shares outstanding, basic (in shares)	41	39	38	37	26
Weighted-average ordinary shares outstanding, diluted (in shares)	41	39	38	38	26
Net loss per share attributable to ordinary shareholders, basic (in usd per share)	−1.64	−1.55	−1.91	0.14	−1.96
Net loss per share attributable to ordinary shareholders, diluted (in usd per share)	−1.64	−1.55	−1.91	0.14	−1.96
Other comprehensive gain/(loss) foreign currency translation adjustments	10	−3	10	−25	−7
Comprehensive loss	−56	−64	−63	−20	−58
Comprehensive loss/(gain) attributable to noncontrolling interest	22,000	105,000	94,000	132,000	250,000
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders	−56	−64	−63	−20	−58

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	70	111	142	194	214
Restricted cash	1	2	0	—	—
Research and development incentives receivable	1	7	5	5	6
Prepaid expenses and other current assets	5	6	10	8	6
Total current assets	78	126	157	213	227
Property and equipment, net	4	7	12	8	2
Intangible assets, net	14	22	25	28	31
Right of use assets, net	2	4	8	8	7
Other assets	930,000	881,000	882,000	976,000	804,000
Total assets	98	160	215	270	281
Accounts payable	350,000	2	2	4	2
Accrued expenses and other current liabilities	6	10	9	8	8
Deferred income	1	2	0	—	—
Operating lease liability - current	2	2	2	433,000	523,000
Total current liabilities	10	16	13	12	11
Operating lease liability - non-current	9	10	11	8	7
Contingent consideration	3	3	2	2	2
Other non-current liabilities	1	1	1	965,000	—
Deferred tax liability, net	254,000	438,000	574,000	—	—
Total liabilities	24	30	28	27	28
Commitments and contingencies (Note 16)	—	—	—	—	—
Ordinary shares, 0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663)	1,000	1,000	1,000	1,000	1,000
Deferred A shares, 1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443)	86,000	86,000	—	—	—
Additional paid-in capital	394	393	387	380	369
Accumulated deficit	−304	−238	−177	−103	−109
Accumulated other comprehensive loss foreign currency translation adjustments	−16	−26	−23	−33	−8
Total stockholders equity attributable to Barinthus Biotherapeutics plc shareholders	74	130	187	243	252
Noncontrolling interest	84,000	106,000	211,000	305,000	437,000
Total stockholders equity	74	130	187	243	253
Total liabilities and stockholders equity	98	160	215	270	281

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share based compensation	468,000	5	5	10	16
Impairment of long-lived assets	6	5	—	—	—
Depreciation and amortization	6	6	5	4	602,000
Non-cash lease expenses	3	1	1	1	338,000
Unrealized foreign exchange loss	4	−649,000	8	−25	—
Change in contingent consideration	26,000	866,000	55,000	−73,000	—
Non-cash interest expense	51,000	48,000	28,000	19,000	813,000
Deferred tax benefit	−175,000	−44,000	−3	−4	−119,000
Profit on sale of property and equipment	−200,000	0	0	−348,000	—
Prepaid expenses and other current assets	2	4	2	−2	−4
Research and development incentives receivable	6	−2	−127,000	1	−4
Accounts payable	−2	898,000	−3	1	−4
Accrued expenses and other current liabilities	−4	456,000	2	751,000	4
Deferred income	−506,000	2	0	—	—
Operating lease liabilities	−2	−2	−445,000	0	—
Net cash used in operating activities	−48	−29	−51	−14	−33
Proceeds from sale of property and equipment	500,000	0	0	388,000	—
Purchases of property and equipment	−37,000	−892,000	−5	−6	−1
Net cash provided by/(used) in investing activities	416,000	−892,000	−5	−6	−13
Issue of shares from the exercise of stock options	2,000	0	0	0	9,000
Proceeds from issue of ordinary shares, net of issuance costs	0	2	2	484,000	103
Net cash provided by financing activities	2,000	2	2	325,000	223
Effect of exchange rates on cash, cash equivalents and restricted cash	7	−2	2	187,000	−6
Net decrease in cash, cash equivalents and restricted cash	−41	−30	−52	−20	171

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro